ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home immunotherapy

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

Mario Lacouture
on: September 17, 2021In: Supportive & Palliative Care
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

Mario Lacouture, MD, is director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center and specializes in the dermatologic side effects of cancer treatment. He is the founder of the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary program bringing together pat... Read more


Therapeutic Vaccine Development in Lung Cancer: Update and Recent Advances

Mohamad Omar Ashi
+more
on: August 27, 2021In: Evolving Standards of Care
Therapeutic Vaccine Development in Lung Cancer: Update and Recent Advances

Most cancer immunotherapies currently in development aim to stimulate antitumor T-cell responses either by adoptive transfer of in vitro expanded native or genetically modified T lymphocytes targeting malignant cells,1 ,2 […] Read more

Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy

on: June 23, 2020In: Meeting News
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor
            Therapy

By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) […] Read more

Systemic Therapy for Advanced Stage Lung Cancer During the COVID-19 Pandemic

on: April 23, 2020In: Meeting News
Systemic Therapy for Advanced Stage Lung Cancer During the COVID-19 Pandemic

Watch Recording IASLC faculty members from Europe, Asia and North America will discuss systemic therapies including chemotherapy, immunotherapy, and targeted therapy for advanced-stage lung cancer during the COVID-19 global pandemic. […] Read more

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

on: April 15, 2020In: Diagnostic Oncology
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more

Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About the Management of Immunotherapy AEs

on: February 11, 2020In: Nursing & Allied Health
Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About the Management of
            Immunotherapy AEs

By Enza Esposito Nguyen, DNP, RN, ANP-BC Posted: February 12, 2020   Dr. Enza Esposito Nguyen Although we continue to see many immunotherapy clinical trials mature and deliver marvelous improvements […] Read more

Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

on: February 11, 2020In: Systemic, Targeted, & Immune Therapies
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status.   […] Read more

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

on: December 10, 2019In: Uncategorized
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated […] Read more

Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data

on: December 10, 2019In: Evolving Standards of Care
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational
            Data

Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. […] Read more

IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy